Intracranial Aneurysms Clinical Trial
— CLASSOfficial title:
Cost Effectiveness, Safety, and Efficacy of the Kaneka iED Coil System for the Treatment of Wide Necked Ruptured and Unruptured Intracranial Aneurysms
NCT number | NCT05636124 |
Other study ID # | STUDY-22-01480 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2, 2023 |
Est. completion date | July 2025 |
This is a multi-center, prospective, propensity matched twin armed study conducted on 50 patients in the experimental arm followed for 18 months after intervention evaluating cost effectiveness, safety and efficacy of therapy.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria: - Patient presenting with ruptured or unruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neuroendovascular treating team - Wide neck side wall or bifurcation intracranial aneurysms (neck > or = to 4 mm or dome-to-neck ratio < 2) within the anterior or posterior circulation - The neurointerventionist feels that the aneurysm can be safely treated using endovascular techniques (direct or assisted coiling) - Patients are 18-80 years of age (inclusive) - Patient must be Hunt and Hess grade 0 to 3 - Patient has given fully informed consent to endovascular coiling procedure. If the patient cannot consent for themselves, appropriate written consent has been sought from their next of kin or appropriate power of attorney. - Aneurysm 6-14 mm in diameter - Patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography) at 3-6 months and 12-18 months after endovascular treatment - The patient has not been previously enrolled in this trial or another related ongoing trial - The aneurysm has not been previously treated by coiling or clipping Exclusion criteria: - Patient has more than one aneurysm requiring treatment in the current treatment session, and only one of those to be treated aneurysms fits the Kaneka inclusion criteria (i.e., - if either (1) a patient has multiple aneurysms, but only one will be treated at enrollment; or (2) if two or more aneurysms are treated during the current treatment session and BOTH are able to be enrolled, then they remain eligible for the trial). Non-treated additional aneurysms may be treated at a later date with any coil type that the operator chooses). - Target aneurysm has had previous coil treatment or has been surgically clipped - Hunt and Hess score is 4 or 5 after subarachnoid hemorrhage - Inability to obtain informed consent - Medical or surgical comorbidity such that the patient's life expectancy is less than 2 years |
Country | Name | City | State |
---|---|---|---|
United States | Sutter Health | Danville | California |
United States | Prisma Health | Greenville | South Carolina |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | University of South Florida | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai | Kaneka Corporation |
United States,
Bairstow P, Dodgson A, Linto J, Khangure M. Comparison of cost and outcome of endovascular and neurosurgical procedures in the treatment of ruptured intracranial aneurysms. Australas Radiol. 2002 Sep;46(3):249-51. doi: 10.1046/j.1440-1673.2002.01053.x. — View Citation
Gandhoke GS, Pandya YK, Jadhav AP, Jovin T, Friedlander RM, Smith KJ, Jankowitz BT. Cost of coils for intracranial aneurysms: clinical decision analysis for implementation of a capitation model. J Neurosurg. 2018 Jun;128(6):1792-1798. doi: 10.3171/2017.3.JNS163149. Epub 2017 Aug 25. — View Citation
Maeda JL, Raetzman SO, Friedman BS. What hospital inpatient services contributed the most to the 2001-2006 growth in the cost per case? Health Serv Res. 2012 Oct;47(5):1814-35. doi: 10.1111/j.1475-6773.2012.01460.x. Epub 2012 Sep 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with Modified Raymond Roy 1-2 Occlusion classification without retreatment | Modified Raymond Roy 1-2 occlusion at 18 months without retreatment. The Raymond-Roy Occlusion Classification has 3 responses, where Grade 1 is complete occlusion, no flow of contrast seen in the sac, Grade 2 is partial occlusion, some flow in the neck or sac, and Grade 3 is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome. | at 18 months | |
Primary | Number of coils used | Number of coils used to assess treatment-related cost effectiveness at treatment and over the course of follow-up to 18 months. | up to 18 months post-treatment | |
Primary | Packing density of coils | Packing density of coils used to assess treatment-related cost effectiveness at treatment and over the course of follow-up to 18 months. | up to 18 months post-treatment | |
Primary | Number of device related serious adverse events | Intra and peri-procedural (0-24 hours) device related serious adverse event rate. | up to 24 hours | |
Primary | Number of device related serious adverse events | Intra and peri-procedural (24 hours to 30 days) device related serious adverse event rate. | 24 hours to 30 days | |
Secondary | Rate of complete or near complete aneurysm occlusion without retreatment | Rate of complete or near complete aneurysm occlusion without retreatment at 6 months | at 6 months | |
Secondary | Number of patients with Modified Raymond-Roy classification 1 | The Raymond-Roy Occlusion Classification has 3 responses, where Grade 1 is complete occlusion, no flow of contrast seen in the sac, Grade 2 is partial occlusion, some flow in the neck or sac, and Grade 3 is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome. | at 18 months | |
Secondary | Number of patients who suffer a Major ipsilateral stroke or neurological death | Number of patients who suffer a Major ipsilateral stroke or neurological death. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause. | at 6 months | |
Secondary | Number of patients who suffer a Major ipsilateral stroke or neurological death | Number of patients who suffer a Major ipsilateral stroke or neurological death. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause. | at 18 months | |
Secondary | Changes in Modified Rankin Scale (mRS) score | The mRS ranges from 0 to 6, with higher scores indicating a greater degree of disability or dependence. Scores will be assigned based on the following:
0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased. Changes in the mRS score will be assessed between day 30, 6 months, and 12-18 months. |
Day 30, 6 months, and 12-18 months | |
Secondary | Changes in National Institutes of Health Stroke Scale (NIHSS) score | The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The total NIHSS score can range from 0 to 42, with 0 indicating no stroke symptoms and 42 indicating extremely severe stroke symptoms. So, a higher NIHSS score indicates a greater degree of impairment. Changes in the NIHSS score will be assessed between day 30, 6 months, and 12-18 months. | Day 30, 6 months, and 12-18 months | |
Secondary | Ratio of packing density to number of coils used | This ratio indicates how many coils were needed to sufficiently pack the aneurysm. A higher ratio of packing density to number of coils used indicates that fewer coils were needed to sufficiently pack the aneurysm. | Treatment, day 1 | |
Secondary | Raymond-Roy occlusion classification (RROC) | Change in the post-coiling appearance of the aneurysm as measured by the Raymond-Roy occlusion classification (RROC) which is an angiographic classification scheme for grading the occlusion of endovascularly treated aneurysms.
class I: complete obliteration class II: residual neck class III: residual aneurysm |
Post-procedure to 18 months | |
Secondary | Change in Occlusion outcome status | Occlusion outcome status may be designated as stable, improved or worse. | baseline and 18 months | |
Secondary | Aneurysm recurrence/coil compaction | Aneurysm recurrence/coil compaction is based on whether the coil has been able to stem blood flow. If coil compaction occurs, the aneurysm may recur. Response will be yes/no. | Post-procedure to 18 months | |
Secondary | Rate of re-treatment or hemorrhage | at 6 months | ||
Secondary | Rate of re-treatment or hemorrhage | at 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02879175 -
Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms
|
||
Completed |
NCT01139892 -
The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES)
|
||
Recruiting |
NCT06411418 -
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm
|
N/A | |
Completed |
NCT02312856 -
Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction
|
N/A | |
Recruiting |
NCT01054391 -
Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae
|
N/A | |
Completed |
NCT02657772 -
Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms
|
||
Completed |
NCT01465841 -
Study of the Penumbra Coil 400 System to Treat Aneurysm
|
N/A | |
Enrolling by invitation |
NCT05453240 -
Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the LVIS Device
|
||
Completed |
NCT03550638 -
Coil System(Ton-bridgeMT) for Endovascular Embolization of Cranial Aneurysms
|
N/A | |
Terminated |
NCT02122133 -
CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400
|
||
Completed |
NCT01541254 -
Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device
|
Phase 2/Phase 3 | |
Terminated |
NCT01320306 -
Intracranial Aneurysms and Cognitive Function
|
||
Recruiting |
NCT01084681 -
Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques
|
N/A | |
Completed |
NCT00396981 -
MAPS Trial: Matrix And Platinum Science
|
Phase 4 | |
Completed |
NCT02921711 -
TRAIL: Treatment of Intracranial Aneurysms With LVIS® System
|
||
Recruiting |
NCT01031147 -
Contrast-free Magnetic Resonance Angiography (MRA) at 3.0 T for Intracranial Aneurysm Detection
|
N/A | |
Completed |
NCT02921698 -
Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment
|
||
Completed |
NCT01801007 -
Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms
|
N/A | |
Terminated |
NCT01974700 -
Seizure Prophylaxis in Aneurysm Repair
|
Phase 4 | |
Completed |
NCT01793792 -
Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)
|
N/A |